Glass House BrandsGLASF -0.80%44 Return-on-Tangible-Equity is -54.34% as of Mar. 2026. GuruFocus rates GLASF with a GF Score™ of 44/100 and a GF Value™ of $6.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 899 Drug Manufacturers companies, Glass House Brands ranks worse than 88.54% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Glass House Brands's annualized net income for the quarter that ended in Mar. 2026 was $-62.0 Mil. Glass House Brands's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $114.1 Mil. Therefore, Glass House Brands's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -54.34%.
The historical rank and industry rank for Glass House Brands's Return-on-Tangible-Equity or its related term are showing as below:
GLASF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -120.07 Med: -41 Max: 0.61
Current: -32.03
During the past 6 years, Glass House Brands's highest Return-on-Tangible-Equity was 0.61%. The lowest was -120.07%. And the median was -41.00%.
GLASF's Return-on-Tangible-Equity is ranked worse than 88.54% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.68
vs GLASF: -32.03
Glass House Brands (OTCPK:GLASF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Glass House Brands Return-on-Tangible-Equity Related Terms
Glass House Brands Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Glass House Brands's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glass House Brands Return-on-Tangible-Equity Chart
GLASF vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Glass House Brands's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glass House Brands Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glass House Brands's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Glass House Brands's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -54.34% mean?
Glass House Brands (GLASF) has a Return-on-Tangible-Equity of -54.34% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Glass House Brands and its competitors. According to the industry distribution chart, Glass House Brands ranks #796 out of 899 companies in the Drug Manufacturers industry, placing it in the top 88.5%.
Is Glass House Brands' Return-on-Tangible-Equity too high?
Glass House Brands' current Return-on-Tangible-Equity is -54.34%. Based on the distribution chart, Glass House Brands ranks #796 out of 899 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Glass House Brands has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glass House Brands' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Glass House Brands ranks #796 out of 899 companies for Return-on-Tangible-Equity. This places Glass House Brands in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.68, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Glass House Brands and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glass House Brands's current Return-on-Tangible-Equity is -54.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glass House Brands stock overvalued right now?
Based on GuruFocus' analysis, Glass House Brands (GLASF) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.15, compared to a current price of $12.64 — trading 105.5% above its estimated fair value. The current Return-on-Tangible-Equity is -54.34%. Glass House Brands' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Glass House Brands (GLASF), the current Return-on-Tangible-Equity is -54.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glass House Brands (GLASF) Overvalued in 2026?
Based on GuruFocus' analysis, Glass House Brands stock appears to be overvalued.
The current stock price of $12.64 is trading 105.5% above its estimated GF Value™ of $6.15.
GuruFocus considers Glass House Brands to be Significantly Overvalued.
Key valuation signals for GLASF:
Return-on-Tangible-Equity: -54.34%
GF Value™: $6.15 vs. price of $12.64 (105.5% above fair value)
No single metric tells the full story. See the GLASF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
44GF Score
Get the complete analysis for GLASF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLASF has been successfully added to your 
